Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Double-blind, Placebo-controlled, Canadian Multicentre Study Comparing Two Treatment Strategies of Dronedarone Administration Following ELECTive caRdioversion for Prevention of Symptomatic Atrial Fibrillation (AF) Recurrence

NCT01026090 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01026090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01026090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Double-blind, Placebo-controlled, Canadian Multicentre Study Comparing Two Treatment Strategies of Dronedarone Administration Following ELECTive caRdioversion for Prevention of Symptomatic Atrial Fibrillation (AF) Recurrence
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Terminated
Start date
November 30, 2009
Completion date
December 31, 2011
Enrollment
292 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation